Followers | 2 |
Posts | 34 |
Boards Moderated | 0 |
Alias Born | 06/06/2017 |
Monday, June 19, 2017 8:11:14 AM
https://www.twst.com/interview/interview-with-the-chairman-and-ceo-isoray-inc-nysemkt
Good intell in there:
TWST: In fiscal year 2016, you had $4.7 million in revenue, with close to 90% of that related to prostate cancer treatment. How quickly do you see some of this revenue diverting to some of these new applications?
Mr. LaVoy: The new applications have been a growing percentage of IsoRay’s business over the past five years. The prostate treatment market represented over 95% of our business five years ago, and over the last two years we have reported that other applications have grown to approximately 12% of IsoRay’s sales. One of the key factors for the surgical applications has been that there has been no reimbursement in place as of yet for these applications. In late 2016, IsoRay collaborated with GammaTile and submitted an application for reimbursement to Medicare for radiation treatment of the brain at the time of surgery. The company also filed for FDA clearance for the device in March 2017.
The GammaTile product was developed by a group of doctors at the highly respected Barrow Neurological Institute. They took a collagen matrix that was developed for brain surgery and inserted our Cesium-131 seeds. In the past radiation was always done after surgery, but with the Cesium-131 application it is performed at the time of surgery. The recurrent brain tumor market is estimated to be approximately 50,000 to 70,000 patients a year. If the reimbursement codes and 510 K clearance is obtained this summer, we will have a new product that could be introduced into the market with significant growth potential over the next one to three years.
TWST: Are you currently selling internationally?
Recent CATX News
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Perspective Therapeutics Announces $87.4 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 02:45:00 PM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement • GlobeNewswire Inc. • 01/22/2024 09:05:00 PM
- Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement • GlobeNewswire Inc. • 01/18/2024 12:00:00 PM
- Perspective Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:05:00 PM
- Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Another Healthcare Stock Stealing The Show • AllPennyStocks.com • 01/09/2024 09:10:00 PM
- Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Perspective Therapeutics Divests Brachytherapy Business • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM